NINDS Intramural Research Support

The NINDS Intramural Program encourages scientific interactions and collaborative research projects. The NINDS supports a number of Core Facilities that provide state-of-the-art equipment and expertise to support intramural investigators. Core Facilities provide shared scientific resources, cutting-edge technologies and novel approaches to support crucial research activities and accelerate scientific discovery.  Additional NINDS-partner and NIH-wide facilities are also available to researchers. These NINDS shared core services are available to NIH employees only. 

Animal Health and Care Section (AHCS) / Animal Care and Use Committee (ACUC)

The Animal Health and Care Section (AHCS)  provides a comprehensive program of animal care and use for intramural investigators. The AHCS, in conjunction with the Animal Care and User Committee (ACUC), participates in assuring that the Institutes' Animal Care Program is in compliance with all applicable regulations, guidelines, and policies.

Quantitative MRI (qMRI) Core Facility

NINDS recently set up the quantitative MRI (qMRI) Core facility under the supervision of the Core Director, Dr. Govind Bhagavatheeshwaran. The primary goal of the core is to provide PIs access to research MRI resources developed within and outside NINDS, and to assist in their implementation as endpoints in clinical trials of neurological diseases. The qMRI Core will primarily focus on groups that lack staff well trained in acquisition and processing of MRI data. The Core facility will help these groups implement the pulse sequences and provide the support needed to perform image analysis in well defined, time limited projects. A few examples of endpoints implemented at the core facility are shown below in Figure 1. The Core facility personnel are also available to work with investigators and their team to develop new markers.

Figure 1. A. Machine learning based brain segmentation showing CSF (blue), gray matter (purple), white matter (yellow), and lesions (red) in an HIV-infected individual (PI: Avi Nath, NINDS). B. Spinal cord cross-sectional area along the length of the cord as an imaging marker for cord atrophy from an individual (PI: Steve Jacobson, NINDS)
Figure 1. A. Machine learning based brain segmentation showing CSF (blue), gray matter (purple), white matter (yellow), and lesions (red) in an HIV-infected individual (PI: Avi Nath, NINDS). B. Spinal cord cross-sectional area along the length of the cord as an imaging marker for cord atrophy from an individual (PI: Steve Jacobson, NINDS). Figure 2. B. showcases the postmortem imaging routinely implemented by the core facility as well as an example of the 3D model and 3D printed cutting box. 

In addition, the core will offer its services for postmortem MRI of the human brain and spinal cord, as well as for MRI-guided tissue slicing using a 3D printed cutting box if requested. There is a growing demand to image fixed human brain, especially entire autopsy specimens. The expertise necessary to acquire and interpret high resolution images from large brain specimens available in-house at the q-MRI Core will be provided to the broader NINDS and NIH community.  

Govind Ghagavatheeshwaran, Ph.D.
Phone: 301-402-6391

Proteomics Core Facility

The Proteomics Core Facility provides amino acid sequencing of purified proteins/peptides for NINDS investigators. The facility is also available for collaborations involving protein/peptide purification and more complicated sequencing strategies.

Core Director

Yan Li, Ph.D.
NINDS Proteomics Core Facility
Phone: 301-402-1690

Scope of the Core Facility

The Core provides amino acid sequencing and mass spectral analysis of proteins and peptides for NINDS investigators. The Core also provides theoretical and technical expertise for the separation and purification of proteins and peptides and performs "Proteomics" type projects including the identification of proteins separated by 1- and 2-D PAGE gels and identification of protein phosphorylation sites.

Core Facility Equipment

  • Agilent Technologies Model 1100 series HPLC Modular System equipped with refrigerated autosampler, diode array UV detector and refrigerated fraction collector for protein and peptide isolation and purification.
  • Applied Biosystems Procise Model 491 pulsed-liquid protein sequencer that performs automated classical Edman degradation.
  • Mass Spectrometers: A) ThermoFinnigan ProteomeX HPLC/ELECTROSPRAY IONIZATION MASS SPECTROMETER (HPLC/ESI/MS) system consisting of a Surveyor Capillary HPLC interfaced to a LCQ Deca XP Plus ion trap ESI Mass spectrometer. This combination enables us to perform automated capillary (0.17 mm columns) RP-HPLC separations of proteolytic digests obtained from minute amounts of proteins (30 ng) in SDS PAGE 1&2D gel slices. The system performs on the fly mass spectral MW measurement and MS/MS sequencing of the resulting peptides. The system also performs automated 2D HPLC\MS\MS proteomics analysis in which protein digests are first separated by strong cation exchange chromatography (SCX) in the first stage followed by a reversed–phase separation in the second stage of each of the SCX fractions. The 2D HLPC is widely seen as complementary to or a replacement of 2D electrophoresis in proteomics. (B) Matrix Assisted Laser Adsorption Ionization Time-Of-Flight MASS SPECTROMETER (MALDI-TOF MS). Applied Biosystems Voyager DE-STR MALDI-TOF. This instrument is capable of extremely high resolution (>30,000 at 12 kDa) and sensitivity for the analysis of peptides and proteins up to 340 kDa. Because of these features in addition to its automation capability, it is the ideal instrument for Large Scale Proteomics projects.
Graphic: An example of protein quantitation analysis. Credit: Yan Li
An example of protein quantitation analysis: The volcano plot (A). 
Graphic: An example of protein quantitation analysis. Credit: Yan Li
(B) A heat map generated from a label-free quantitation project. The goal of A and B is to differentiate binding partners of the bait from non-specifically bound background after immunoprecipitation.
Graphic: An example of PTM analysis, mapping Glycylation on beta I tubulin. Credit: Yan Li
An example of PTM analysis, mapping Glycylation on beta I tubulin.

Publications Using the Core

Szajner, P., Jaffe, H, Weisberg, A.S. and Moss, B., Vaccinia virus G7L protein interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions, J. Virol., 77(6), 3418-3429, 2003.

Li, B.S., Ma, W., Jaffe, H., Zheng, Y., Takahashi, S., Zhang, L., Kulkarni, A.B. and Pant, H.C., Cyclin-dependent kinase 5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival, J. Biol. Chem., 278(37), 35702-35709, 2003.

Reddy, P.T., Prasad, C.R., Reddy, P.H., Reeder, D., McKenney, K., Jaffe, H., Dimitrova, M.N., Ginburg, A., Peterkofsy, A. and Murthy, P.S., Cloning and expression of a gene for a novel protein from Mycobacterium smegmatis with functional similarity to eukaryotic calmodulin, J. Bacteriol., 185(17), 5263-5268, 2003.

Jaffe, H., Vinade, L. and Dosemeci, A., Phosphoproteins in the postsynaptic density: a proteomic analysis, submitted to Biochem, 2003.

Sieckmann, D.G., Jaffe, H., Golech, S., Cai, D-G, Hallenbeck, J.M. and McCarron, R.M., Alpha-2-macroglobulin is a growth regulatory protein in plasmas of hibernating 13-lined ground squirrels and woodchucks, submitted to Am. J. Physiol. 2003.

Das S, Gerwin C. and Sheng, Z.H., Syntaphilin binds to dynamin-1 and inhibits dynamin-dependent endocytosis, J Biol Chem., 278(42): 41221-41226, 2003 (Acknowledgment).

Flow and Imaging Cytometry Core Facility

The Flow & Imaging Cytometry Core Facility provides intellectual, technical, training and collaborative support to NINDS and other intramural investigators in both basic and clinical research programs requiring seamless and productive use of conventional flow cytometry, imaging flow cytometry, preparative fluorescence-activated cell sorting (FACS) and in situ cytometric imaging techniques to assay cell biology at the molecular, subcellular and cellular levels, as specified by the investigator. Depending on the investigator's requirements, the Facility provides high-throughput screening of cells and assaying of their specific biological properties, in addition to preparative sorting of purified cell populations and/or subpopulations of interest, based on one of more specific cellular/subcellular parameters, as specified by the investigator. Facility staff is also continuously engaged in research and development of novel methodological approaches to comprehensively study systems biology in the brain using animal models for specific neurological and neurodegenerative disorders (ischemic and traumatic brain injuries, brain tumors, aging brain, select transgenic animal models of neurodevelopmental and neurodegenerative diseases, etc.), for which they combine up to 100-plex biomarker immunohistology screening with multi-spectral fluorescence imaging and multi-parametric big image data analyses.

Flow Cytometry

Core Staff:

Dragan Maric, Ph.D., Core Director
Phone: (301) 402-1406

Andrea Sedlock, M.S., Biologist
Phone: (301) 402-6934


Scope of the Core Facility

The primary mission of the Facility is to provide intellectual, technical, collaborative and new application research and development support to NINDS and other intramural investigators in both basic and clinical research programs requiring the use of high-throughput conventional flow cytometry (CFC), imaging flow cytometry (IFC), preparative fluorescence-activated cell sorting (FACS) and multi-spectral in situ cytometric imaging (ISCI). The Facility currently provides routine use of CFC, IFC, FACS and ISCI applications in assaying a multitude of biological properties at the cellular, subcellular and molecular levels, as specified by the investigator. Critical to these activities is the research and development of a wide variety of novel, customized and standardized multiplex biomarker screening protocols using unique combinations of fluorescent reporters of interest, including those identifying different stages of cell proliferation and differentiation, as well as different types of cell death (i.e., apoptotic, necrotic, cytotoxic, autophagy), in addition to those assaying functional gene expression and cell signaling. The aim of these protocols is to maximize the simultaneous detection and quantification of multiple biological properties per cell and its subcellular compartments (i.e., plasma membrane, cytoplasm, nucleus, mitochondria, lysosomes, synaptosomes, microvesicles, exosomes), utilizing an array of appropriate cell surface, cytoplasmic, nuclear, protein and gene expression biomarkers, as well as select physiological indicator dyes (potentiometric, calcium, pH, live/dead), linked to fluorescent endpoints. Depending on the investigator’s requirements, the Facility provides high-throughput screening of cells and assaying of their specific biological properties, in addition to preparative sorting of purified cell populations and/or subpopulations of interest, based on one or more specific cellular/subcellular parameters, as specified by the investigator. Additional responsibilities of the Facility personnel include regular maintenance and technological upgrades of all instruments that are managed by the Facility, as well as daily instrument alignment and calibration, setting up sample quality controls and standardization, and enabling seamless data acquisition and analysis, presentation and interpretation of the resulting findings to the investigator, and, if requested by the investigator, manuscript preparation and critical review.

Core Facility Equipment

The Facility provides seamless utilization of the following equipment: MoFlo Astrios cell sorter (Beckman Coulter), ImageStreamX flow cytometer (Amnis Corporation) and AxioImager.Z2 10-channel wide-field fluorescence microscope with motorized scanning stage (Carl Zeiss). The optical configurations and services currently provided with each instrument are listed below:

MoFlo Astrios

Services - conventional flow cytometry (CFC) and preparative cell sorting (FACS)
Excitation - 7 air-cooled lasers (355, 405, 488, 532, 561, 592, 640 nm)

- up to 30 (peak emissions ranging from near-UV to near-IR spectrum)
- 20x20 digital compensation matrix for spectrally overlapping dyes

- DAPI, FITC, PE, PE-TR, PE-Cy5, PE-Cy7, Pacific Blue, Pacific Orange
- Alexa 350, 405, 488, 546, 594, 647, 700, 750 or their DyLight equivalents
- Hoechst 33342 (blue/red emissions), PI, GFP, YFP, Venus, tdTomato, mCherry
- Qdot 525, 545, 565, 585, 605, 625, 655, 800
Acquisition - up to 1x105 cells/sec, up to 1x109 cells per acquisition
Sorting - simultaneous 6-way sorting (enrich, pure, single cell)
- up to 5x104 sorted cells/sec
- sort collection (1.5-50 ml tubes, 6-96 well plates, 1x3” microscope slides)
Bioassays - cell cycle and mitosis (DNA content, BrdU incorporation)
- cell death (apoptosis, necrosis, cytotoxicity)
- cell phenotyping (any combination of 20 fluorescent biomarkers)
- cell signaling (potentiometric, calcium flux, protein phosphorylation)
- gene expression (GFP+, YFP+, RFP+ transfected, transduced, transgenic cells)
- preparative cell sorting on any combination of up to 20 fluorescent biomarkers

ImageStreamX Flow Cytometer

Amnis® ImageStream®X Mk II
Services - imaging flow cytometry (IFC)
Excitation - up to 7 air-cooled lasers (3 currently available: 405, 488, 658 nm)
Emission  - up to 10 (peak emissions ranging from near-UV to near-IR spectrum)
- 10x10 digital compensation matrix for spectrally overlapping dyes
Dyes - DAPI, FITC, PE, PE-TR, PE-Cy5, PE-Cy7, Pacific Blue, Pacific Orange
- Alexa 405, 488, 633, 647 or their DyLight equivalents, APC, APC-Cy7
- GFP, YFP, RFP, Qdot 525, 545, 565, 585, 605, 625, 655, 800
Acquisition - up to 2x103 imaged cells/sec, up to 1x105 imaged cells per acquisition
Bioassays - cell cycle and mitosis (DNA content, BrdU incorporation, stages of cell mitosis)
- cell death (apoptosis, necrosis, cytotoxicity, autophagy)
- cell phenotyping (any combination of 10 fluorescent biomarkers)
- cell signaling (intracellular protein trafficking, phosphorylation, enzyme activity)
- cell-cell interactions (intercellular protein trafficking, immune synapse, etc.)
- translocation (membrane to cytoplasm or vice versa, cytoplasm to nucleus, etc.)
- co-localization (ligand-receptor, two or more receptor subunits, enzyme-substrate)
- gene expression (GFP+, YFP+, RFP+ transfected, transduced, transgenic cells)
- internalization (pinocytosis, phagocytosis)

AxioImager.Z2 Scanning Widefield Fluorescence Microscope

image 18
Services - multispectral in situ cytometric imaging (ISCI) Excitation
Excitation - mercury arc lamp (light filtered using 10 spectrally-compatible exciter filters) 
Emission  - up to 10 (peak emissions ranging from near-UV to near-IR spectrum)
Dyes  - Alexa 350, 405, 430, 488, 546, 594, 647, 700, 750, IRDye800CW, PerCP
Acquisition - scan areas up to 1 cm2 in brightfield and up to 10 fluorescence channels
Bioassays - cell cycle and mitosis (DNA content, BrdU incorporation, stages of cell mitosis)
- cell death (apoptosis, necrosis, cytotoxicity, autophagy, cell morphology)
- cell phenotyping (any combination of 10 fluorescent biomarkers)
- cell signaling (intracellular protein trafficking, phosphorylation, enzyme activity)
- cell-cell interactions (intercellular protein trafficking, immune synapse, etc.)
- gene expression (GFP+, YFP+, RFP+ transfected, transduced, transgenic cells)
- systems biology (whole embryo and brain scans, phenotyping tissue cytoarchitecture)


How to Use the Core Facility

To schedule an appointment, please contact the Core Director by e-mail (, phone (301-402-1406) or stop by the Core Facility (Building 10, Room 5S-241) to sign in the scheduling calendar. If new to flow and imaging cytometry or unsure how to best utilize the resources available at the Core, the Core Director will be available to assist the investigator using the following workflow:

Step 1 - Initial consultation with initiating investigator to determine optimal experimental designs tailored to investigator’s interests. The investigator is also familiarized with all the bioassays that have been standardized and are routinely available at the Core Facility.

Step 2 - If standard bioassays currently provided by the Core are not adequate, the  Core Director will work with the investigator to conduct new research and development of customized applications to meet the investigator’s requirements.

Step 3 - Pilot experiments are carried out first to empirically optimize the bioassays using quality controls for verifying sample integrity and identifying specific endpoints of fluorescent reporters, while at the same time discriminating against possible artifacts and non-specific signals.

Step 4 - Once optimized and standardized, the bioassays are available to the investigator for routine use. If problems are encountered with the instrumentation, samples or bioassays, the Core Director will be available to troubleshoot the problems and provide optimal solutions to correct the problems.

Selected Publications Using the Core

Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, Adamstein N, Wang X, Edwards NA, Wu T, Maric D, Giles AJ, Gilbert MR, Quezado M, Nduom EK (2018) Programmed death ligand 1 is a negative prognostic marker in recurrent isocitrate dehydrogenase-wildtype glioblastoma. Neurosurgery 2018 Jul 12. doi: 10.1093/neuros/nyy268. PMID: 30011045.

Hao S, Song H, Zhang W, Seldomridge A, Jung J, Giles AJ, Hutchinson MK, Lita A, Larion M, Maric D, Abu-Asab M, Kramp T, Camphausen K, Zhuang Z, Gilbert MR, Park DM (2018) Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. Neuro-Oncology 2018 May 18;20(6):799-809. PMID: 29294092.

Sapio MR, Neubert JK, LaPaglia DM, Maric D, Keller JM, Raithel SJ, Rohrs EL, Anderson EM, Butman JA, Caudle RM, Brown DC, Heiss JD, Mannes AJ, Iadarola MJ (2018) Pain control through selective chemo-axotomy of centrally projecting TRPV1+ sensory neurons. J Clin Invest 2018 Apr 2;128(4):1657-1670. doi: 10.1172/JCI94331. Epub 2018 Mar 19. PMID: 29408808.

Su YT, Chen R, Wang H, Song H, Zhang Q, Chen LY, Lappin H, Vasconcelos G, Lita A, Maric D, Li A, Celiku O, Zhang W, Meetze K, Estok T, Larion M, Abu-Asab M, Zhuang Z, Yang C, Gilbert MR, Wu J (2018) Novel targeting of transcription and metabolism in glioblastoma. Clin Cancer Res 2018 Mar 1;25(5):1124-1137. PMID: 29254993.

Ho WSC, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM (2018) LB-100, a novel protein phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett 2018 Feb 28;415:217-226. PMID: 29199006.

Bernstock JD, Ye DG, Griffin A, Lee YJ, Lynch J, Latour LL, Friedman GK, Maric D, Hallenbeck JM (2018) Cerebral ischemia increases small ubiquitin-like modifier conjugation within human penumbral tissue: radiological-pathological correlation. Front Neurol. 2018 Jan 12;8:738. PMID: 29375471.

Bernstock JD, Ye D, Gessler FA, Lee YJ, Peruzzotti-Jametti L, Baumgarten P, Johnson KR, Maric D, Yang W, Kogel D, Pluchino S, Hallenbeck JM (2017) Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming. Sci Rep 7:7425. PMID: 28785061.

Lu J, Chatain GP, Bugarini A, Wang X, Maric D, Walbridge S, Zhuang Z, Chittiboina P (2017) Histone deacetylase inhibitor SAHA is a novel, promising treatment for Cushing's Disease. J Clin Endocrinol Metab 102: 2825-2835. doi: 10.1210/jc.2017-00464. PMID: 28505327.

Pandya H, Shen MJ, Ichikawa DM, Sedlock A, Choi Y, Johnson KR, Kim G, Brown MA, Elkahloun A, Maric D, Sweeney CL, Gossa S, Malech HL, McGavern DB, Park JK (2017) Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat Neurosci 20:753-759. PMID: 28253233.

Sizdahkhani S, Feldman MJ, Piazza MG, Ksendzovsky A, Edwards NA, Ray-Chaudhury A, Maric D, Merrill MJ, Pacak K, Zhuang Z, Chittiboina P (2017) Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Sci Rep 7:40822. PMID: 28094316.

Bott LC, Salomons FA, Maric D, Liu Y, Merry D, Fischbeck KH, Dantuma NP (2016) The polyglutamine-expanded androgen receptor responsible for spinal and bulbar muscular atrophy inhibits the APC/C(Cdh1) ubiquitin ligase complex. Sci Rep 6:27703.

Komori M, Lin YC, Cortese I, Blake A, Ohayon J, Cherup J, Maric D, Kosa P, Wu T, Bielekova B (2016) Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol 3:166-179.

Ho WS, Feldman MJ, Maric D, Amable L, Hall MD, Feldman GM, Ray-Chaudhury A, Lizak MJ, Vera JC, Robison RA, Zhuang Z, Heiss JD (2016) PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Oncotarget 7:12447-12463.

Bernstock, JD, Lee YJ, Peruzzotti-Jametti L, Southall N, Johnson KR, Maric D, Volpe G, Kouznetsova J, Zheng W, Pluchino S, Hallenbeck JM (2016) A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. J Cereb Blood Flow Metab 36:426-441.

Li W, Lee MH, Henderson L, Tyagi R, Bachani M, Steiner J, Campanac E, Hoffman DA, von Geldern G, Johnson K, Maric D, Morris HD, Lentz M, Pak K, Mammen A, Ostrow L, Rothstein J, Nath A (2015) Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med 7:307ra153.

Feldman M, Piazza MG, Edwards NA, Ray-Chaudhury A, Maric D, Merrill MJ, Zhuang Z, Chittiboina P (2015) Somatostatin receptor expression on VHL-associated hemangioblastomas offers novel therapeutic target. Neurosurgery. Neurosurgery 62 Suppl 1:209-210.

Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese IC, Ohayon J, Fenton K, Reyes-Mantilla M, Maric D, Calabresi PA, Butman JA, Pardo CA, Reich DS (2015) Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 85:18-28.

Salvucci O, Ohnuki H, Maric D, Hou, X, Li X, Yoon SO, Segarra M, Eberhart CG, Acker-Palmer A, Tosato G (2015) EphrinB2 controls vessel pruning through STAT1-JNK3 signaling. Nat Commun 6:6576.

Brachman RA, Lehmann ML, Maric D, Herkenham M (2015) Lymphocytes from chronically stressed mice confer antidepressant-like effects to naive mice. J Neurosci 35:1530-1538.

Goswami SC, Mishra SK, Maric D, Kaszas K, Gonnella GL, Clokie SJ, Kominsky HD, Gross JR, Keller JM, Mannes AJ, Hoon MA, Iadarola MJ (2014) Molecular signatures of mouse TRPV1-lineage neurons revealed by RNA-Seq transcriptome analysis. J Pain 15:1338-1359.

Ohnuki H, Jiang K, Wang D, Salvucci O, Kwak H, Sánchez-Martín D, Maric D, Tosato G (2014) Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression. Cancer Res 74:2038-2049.

Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R, Nath A (2013) Induction of IL-17 and non-classical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci USA 110:13588-13593.

Hunsberger JG, Fessler EB, Chibane FL, Leng Y, Maric D, Elkahloun AG, Chuang DM (2013) Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions. Am J Transl Res 5:450-464.

Segarra M, Ohnuki H, Maric D, Salvucci O, Hou X, Kumar A, Li X, Tosato G (2012) Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood 120:4104-4115.

Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R, Tosato G (2012) Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. Cancer Res 72:1157-1169.

Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, Ding J, Maric D, Jaffe H, Cookson MR (2012) The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson’s disease is a partial loss-of-function mutation. Biochem J 446:99-111.

Harberts E, Yao K, Wohler JE, Maric D, Ohayon J, Henkin R, Jacobson S (2011) Human herpesvirus-6 entry into the central nervous system through the olfactory pathway. PNAS 108:13734-13739.

Lee Y-J, Mou Y, Maric D, Klimanis D, Auh S, Hallenbeck J (2011) Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One 6(10):e25852.

Wuchty S, Arjona D, Li A, Kotliarov Y, Walling J, Ahn S, Zhang A, Maric D, Anolik R, Zenklusen JC, Fine HA (2011) Prediction of associations between microRNAs and gene expression in glioma biology. PLoS One 6(2):e14681.

Edwards LA, Woolard K, Son MJ, Li A, Lee J, Ene C, Mantey SA, Maric D, Song H, Belova G, Jensen RT, Zhang W, Fine HA (2011) Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst 103:1162-1178.

Wuest S, Han S, Martin J, Maric D, Bielekova B (2011) Vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy. Nature Medicine 17:604-609.

Bogoslovsky T, Spatz M, Chaudhry A, Maric D, Luby M, Frank J, Warach S (2011) Stromal derived factor-1a correlates with circulating endothelial progenitor cells and with acute lesion volume in stroke patients. Stroke 42:618-625.

Suen DF, Narendra DP, Tanaka A, Manfredi G, Youle RJ (2010). Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proc Natl Acad Sci 107:11835-11840.

Fukunaga M, Li TQ, van Gelderen P, de Zwart JA, Shmueli K, Yao B, Lee J, Maric D, Aronova MA, Zhang G, Leapman RD, Schenck JF, Merkle H, Duyn JH (2010) Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci 107:3834-3839.

Zheng YL, Li BS, Rudrabhatla P, Shukla V, Amin ND, Maric D, Kesavapany S, Kanungo J, Pareek TK, Takahashi S, Grant P, Kulkarni AB, Pant HC (2010) Phosphorylation of p27Kip1 at Thr187 by cyclin-dependent kinase 5 modulates neural stem cell differentiation. Mol Biol Cell 21:3601-3614.

Chen BS, Roche KW (2009) Growth factor-dependent trafficking of cerebellar NMDA receptors via protein kinase B/Akt phosphorylation of NR2C. Neuron 62:471-478.

Son MJ, Woolard K, Nam DH, Lee J, Fine HA (2009) SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4:440-452.

Lee Y-J, Castri P, Bembry J, Maric D, Hallenbeck J (2009) SUMOylation participates in induction of ischemic tolerance. J Neurochem 109:257-267.

Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM (2009) Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T cell induction after stroke in spontaneously hypertensive rats. J Cereb Blood Flow Metab 29:606-620.

Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S (2009) Regulatory T cells are reduced during anti-CD25 antibody treatment for multiple sclerosis. Arch Neurol 66:471-479.

Sumner JP, Shapiro EM, Maric D, Conroy R, Koretsky AP (2009) In vivo labeling of adult neural progenitors for MRI with micron sized particles of iron oxide: Quantitation of labeled cell phenotype. Neuroimage 44:671-678.

Lee J, Son MJ, Woolard, K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, Kim MS, Totonchy M, Cusack T, Ene C, Ma H, Su Q, Zenklusen JC, Zhang W, Maric D, Fine HA (2008) Epigenetic-mediated dysfunction of the bone morphogenic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13:69-80.

Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, Fine HA (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68:6643-6651.

Lau P, Verrier JD, Nielsen JA, Johnson KR, Notterpek L, Hudson LD (2008) Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci 28:11720-11730.

Lee Y-J, Miyake S, Wakita H, McMullen DC, Azuma Y, Auh S, Hallenbeck JM (2007) Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells. J Cereb. Blood Flow Metab 27:950-962.

Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov Y, Zenklusen JC, Fine HA, Maric D, Wen PY, De Girolami U, Black PM, Wu WW, Shen RF, Jeffries NO, Kang DW, Park JK (2007) The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 99:639-652.

Glod J, Kobiler D, Noel M, Koneru R, Lehrer S, Medina D, Maric D, Fine HA (2006) Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood 107:940-946.

Chen BS, Braud S, Badger JD 2nd, Isaac JT, Roche KW (2006) Regulation of NR1/NR2C N-methyl-D-aspartate (NMDA) receptors by phosphorylation. J Biol Chem 281:16583-16590.

Nielsen JA, Maric D, Lau P, Barker JL, Hudson LD (2006) Identification of a novel oligodendrocyte cell adhesion protein using gene expression profiling. J Neurosci 26:9881-9891.

Nasu-Nishimura Y, Hurtado D, Braud S, Tang TT, Isaac JT, Roche KW (2006) Identification of an endoplasmic reticulum-retention motif in an intracellular loop of the kainate receptor subunit KA2. J Neurosci 26:7014-7021.

Yamano Y, Takenouchi N, Li HC, Tomaru U, Yao K, Grant CW, Maric D, Jacobson S (2005) Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest 115:1361-1368.

Purow B, Haque RH, Noel MN, Su Q, Lee J, Burdick M, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG, Fine HA (2005) Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65:2353-2363.

Lawrence DM, Durham LC, Schwartz L, Seth P, Maric D, Major EO (2004) Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol 78:7319-7328.

Nadareishvili ZG, Li H, Wright V, Maric D, Warach S, Hallenbeck JM, Dambrosia J, Barker JL, Baird AE (2004) Elevated pro-inflammatory CD4+CD28- lymphocytes and stroke recurrence and death. Neurology 63:1446-1451.

Cohen RI, Rottkamp DM, Maric D, Barker JL, Hudson LD (2003) A role for semaphorins and neuropilins in oligodendrocyte guidance. J Neurochem 85:1262-1278.

Tomaru U, Yamano Y, Nagai M, Maric D, Kaumaya PT, Biddison W, Jacobson S (2003) Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nature Medicine 9:469-476.

The Biospecimen Core

The Biospecimen Core was established in the fall of 2021, to provide sample acquisition andprocessing, sample tracking, storage, and sample shipment support. The core will first focus onestablishing standard operating procedures, and maintaining a database on clinical information andlaboratory results on each of patients from whom the specimens are acquired. (Biospecimen Director: Niru Amin)

Light Imaging Core Facility

The Light Imaging Core Facility provides intramural scientists with access to state-of-the-art light imaging equipment and expertise in light imaging techniques. Click for more information.

Porter Neuroscience Research Center
Building 35, Room 2B1016
35 Convent Drive, MSC 4062
Bethesda, MD 20892-4062
Phone: 301-496-8893

Electron Microscopy (EM) Core Facility

The EM Core Facility  provides intramural NINDS investigators with the opportunity to use electron microscopic techniques in their research programs. The staff provide assistance in all aspects of electron microscopy including project planning, specimen preparation and training.

Pictured left to right: Rita Azzam, Dr. Cheng, and Virginia Tanner-Crocker
Pictured left to right: Rita Azzam, Dr. Cheng, and Virginia Tanner-Crocker

Core Staff

Susan J. H. Tao Cheng, Ph.D., Core Director
Phone: 301-496-0579

Rita Azzam, Biologist
Virginia Tanner-Crocker, B.S., Biologist    

Scope of the Core Facility

The Facility is dedicated to providing the scientific community within NINDS equipment for transmission electron microscopy . The Facility also offers expertise in the use and application of microscopy to a wide variety of scientific problems. Highly competent technical staff provide all users access to routine as well as customized protocols involving fixation, embedding, sectioning and examination of samples. Pre- and Post-embed labeling procedures are available.

Core Facility Equipment

JEOL 1200 EXII Transmission Electron Microscope
JEOL 200 CX Transmission Electron Microscope
AMT digital camera system (XR-100 ) on both microscopes
Leica Ultracut E Ultramicrotomes
Histology And Diamond Knives

Publications Using the Core

Levy JR, Sumner CJ, Caviston JP, Tokito MK, Ranganathan S, Ligon LA, Wallace KE, LaMonte BH, Harmison GG, Puls I, Fischbeck KH, Holzbaur EL. (2006) A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J Cell Biol. 172:733-745.

Zhang J, Diamond JS.    Distinct perisynaptic and synaptic localization of NMDA and AMPA receptors on ganglion cells in rat retina. (2006) J Comp Neurol. 498:810-820.

Chang KT, Min KT. (2005) Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function. Nat Neurosci. 8:1577-1585.

Tian JH, Wu ZX, Unzicker M, Lu L, Cai Q, Li C, Schirra C, Matti U, Stevens D, Deng C, Rettig J, Sheng ZH. (2005) The role of Snapin in neurosecretion: snapin knock-out mice exhibit impaired calcium-dependent exocytosis of large dense-core vesicles in chromaffin cells. J Neurosci. 25:10546-10555.

Donati D, Martinelli E, Cassiani-Ingoni R, Ahlqvist J, Hou J, Major EO, Jacobson S. (2005) Variant-specific tropism of human herpesvirus 6 in human astrocytes. J Virol. 79:9439-9448


Viral Production Core Facility

The Viral Production Core Facility produces preclinical grade viruses for NIH investigators. The facility has produced Lentivirus, AAV virus and Rabies viral vectors. The Facility can provide the plasmid DNA cloning for viral vector production as well as viral packaging from plasmids produced outside of the facility. The Facility is also available for consultation and advice on the use of lenti and AAV viral vectors as well as production of novel viral vectors.

Contact Information

Raymond Field, B.S., Core Director
NINDS Viral Production Core Facility
Phone: 301-496-9917
Fax: 301-496-1339

Scope of the Core Facility

The Viral Production Core Facility produces preclinical grade viruses for NIH investigators. The facility has produced Lentivirus, AAV virus and Rabies viral vectors. The Core can provide the plasmid DNA cloning for viral vector production as well as viral packaging from plasmids produced outside of the facility. The Core is also available for consultation and advice on the use of lenti and AAV viral vectors as well as production of novel viral vectors.


Translational Neuroscience Center (TNC)

The Translational Neuroscience Center  provides an infrastructure to assist researchers in pre-clinical and clinical studies to develop new diagnostics and treatments for neurological diseases. The TNC is comprised of three units described below.

  • Drug Development Unit, directed by Dr. Joseph Steiner
    The Drug Development Unit provides assistance with development of throughput assays for identified targets for drug development using primary brain cells or stem cell derived neuronal and glial cells. 
  • Neurodifferentiation Unit, directed by Dr. David Wang
    The Neurodifferentiation Unit delineates new techniques for converting blood derived stem cells into neurons to develop personalized medicine and study disease pathogenesis.
  • Clinical Proteomics Unit, directed by Dr. Jeffrey Kowalak
    The Clinical Proteomics Unit uses state-of-the-art mass spectroscopy based techniques to decipher the proteome in the cerebrospinal fluid and other biological materials.

For additional information about the TNC contact:


Bioinformatics Core

The Bioinformatics Core is located in Building 10 (3B01) and consists of both Bioinformatics Scientist-staff and Bioinformatics Programmer-staff. It's mission is to collaboratively assist NINDS research staff with Bioinformatics-related projects as needed..

Pictured:  Amar Yavatkar, Bioinformatics Programmer and Kory Johnson, Ph.D., Bioinformatics Scientist (left to right)
Pictured:  Amar Yavatkar, Bioinformatics Programmer and Kory Johnson, Ph.D., Bioinformatics Scientist (left to right).

Types of Bioinformatics-related projects the Core’s scientific staff can assist with includes:

  • Experiment design
  • Microarray Analysis (one-color, two-color)
  • Next Generation Sequence Analysis (e.g., bulk RNA-Seq, ChIP-Seq, DNA-Seq, scRNA-Seq, TCR-Seq)
  • Protein Analysis (structure prediction, mass spectrometry-based analysis)
  • RNA Analysis (structure prediction, function classification, target prediction)
  • Sequence Analysis (e.g., pair-wise, multiple-alignment, phylogenetics, gene prediction, comparative genomics)
  • Ad-hoc Statistical Analysis (Descriptive, Correlation-based, Comparison Testing, Classification Modeling)

Types of Bioinformatics-related projects the Core's programming staff can assist with includes:

  • Application design, development, & maintenance
  • Database design, development, & maintenance
  • Dashboard design, development, & maintenance
  • Systems design, development, & maintenance

In addition to providing both Bioinformatics Scientist and Bioinformatics Programmer assistance to NINDS research staff, the Core staff also serves as mentors in the NIH Summer Internship Program each year.

If you should need Bioinformatics-related assistance per your research, certainly contact us today, we are here for you:


Clinical Trials Unit

puzzle pieces

As part of the Office of the Clinical Director, the Clinical Trials Unit (CTU) is a group of clinical research experts who collaborate to provide NINDS intramural investigators with support in developing and executing clinical research studies, as well as regulatory guidance.  CTU members have extensive experience and knowledge regarding clinical research regulations, IRB and scientific review procedures, protocol navigation, protocol development, safety oversight, regulatory support, protocol auditing and monitoring, as well as statistical plan development and analysis. 

The mission of the Clinical Trials Unit (CTU) is to create an environment for state-of-the-art clinical trials to promote successful integration into the translational development of treatments of neurological disease.

Aims and Goals

As a core unit under the NINDS Office of the Clinical Director, the CTU aims to support and facilitate clinical research at the NINDS intramural research program by providing assistance and resources to investigators throughout the life cycle of a protocol; from protocol development, start-up, and execution to data analysis and reporting.

It is the goal of the NINDS CTU to ensure quality science and the protection of human subjects participating in research in the NINDS intramural research program.  In an effort to advance these goals, the NINDS CTU provides oversight of clinical research conducted by NINDS intramural investigators and provides education and training opportunities to all members of the clinical research study team.

The NINDS CTU is dedicated to promoting the advancement of clinical trial methodology through research collaborations with clinical investigators at NINDS as well as outside partners.


The Office of Biostatistics; Tianxia Wu, Ph.D.

The Office of Biostatistics (OB) is an office within the Clinical Trials Unit (CTU), Office of the Clinical Director (OCD) at the NINDS. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.  The OB contributes to the NINDS mission by providing objective, high-quality statistical solutions through proper implementation of statistical methods and by promoting the use of rigorous quantitative methods. For additional information, contact the Office of Biostatistics at

The Office of Quality Assurance and Data Management; Sandra Martin, M.S.

The Quality Assurance and Data Management Office (QADMO) is located  in the NINDS Clinical Trials Unit within the Office of the Clinical Director. The QADMO assists the Clinical Neuroscience Program by disseminating NIH and FDA policy and guidelines and by providing assistance to clinical research teams to ensure compliance with good clinical practice guidelines. 

The Quality Assurance section provides oversight of protocols to ensure compliance with the protocol and applicable policy, by performing random and for-cause quality assurance audits of intramural research protocols and on-going monitoring of FDA-regulated protocols.

The Data Management section assists study teams with the development of protocol specific data management plans and database systems for the accurate collection, recording and storage of study related data.

The Research Staffing Support Office; Rosalind Hayden, R.N.

The Research Staffing Support Office is an office in the NINDS Clinical Trials Unit within the Office of the Clinical Director.  The RSSO assists the Clinical Neuroscience Program by supporting the PIs and research support staff in 3 key areas.

  • The RSSO Protocol Navigation Team provides navigation and protocol writing services for assigned groups.
  • The RSSO Patient Care Coordinator provides patient care coordination services for assigned groups.
  • The RSSO assists with standardization of the hiring, training, and mentoring process for NINDS research support staff, including Protocol Navigators, Research Coordinators (RN and non-RN), and Patient Care Coordinators.

The Research Training and Education Office; Sandra Bonifant, M.S., CIP

The Research Training and Education (RTE) Office is housed within the Clinical Trials Unit (CTU) of the NINDS Office of the Clinical Director. The RTE office will centralize core regulatory and educational training for investigators and staff, provide oversight of clinical research activities, and be responsible for liaising with multiple departments and agencies, both within and outside of NIH. The RTE office provides a single point of contact for identifying and clarifying diverse mandates and complex policies necessary to conduct clinical trials at NIH and is tasked with identifying, evaluating and ensuring compliance with various training requirements of NINDS employees and volunteers in order to carry out NINDS mission.

The Safety Oversight and Regulatory Compliance Office; Lauren Reoma, M.D.

The Safety Oversight and Regulatory Compliance Office (SORC) is responsible for overseeing all processes involved in centrally supporting NINDS sponsored Investigational New Drug (IND) and Investigational Device Exemption (IDE) clinical trials that are regulated by the U.S. Food and Drug Administration (FDA), including coordination across the Clinical Trial Unit (CTU)  for goal-directed research implementation.

The Office of Clinical Trials Administrative Support; Bradley Alvarez, B.A.

The Office of Administrative Support provides administrative support to the NINDS Scientific Review Committee as well as the NINDS Clinical Trials Unit.

  • Support of the Scientific Review Committee
    Following Standards for Clinical Research within the NIH Intramural Research Program, as established by the NIH Clinical Center Medical Executive Committee, all protocols involving human subjects must undergo review of scientific content by an Institute’s scientific review committee. For NINDS, this function is carried out by the Scientific Review Committee (SRC). The role of the SRC is to review each NINDS research study for scientific merit and contribution to the research mission of NINDS and at time of initial submission. SRC is furthermore tasked to review the impact on central resources for each study. The Office of Administrative Support provides operational and administrative support, including logistics, meeting preparation, and summary minutes for the SRC, as well as coordinates with other entities at NIH (e.g., Chief Scientific Officer of the Clinical Center, NIH IM IRB, etc.) to ensure all requirements for protocols at NINDS are met in order to proceed to IRB review and subsequent study implementation. The Office of Administrative Support provides process audits of the new central IRB Integrated Research Information System (iRIS) to ensure that all necessary study actions are first routed to SRC before IRB review.
  • Support of NINDS Clinical Trials Unit
    The Administrative Support Office provides assistance to all CTU offices by coordinating the budget and supply ordering, IT equipment tracking, coordination of all aspects of travel, meeting coordination and scheduling, centralizing and cataloguing the contracts that CTU uses for protocol support services, as well as providing tracking and auditing of CTU resources and support needs as an entire unit.


Neurology Consult Service

Sophie Cho, M.D., Director, Neurology Consultation Service and Clinic Director

The NINDS intramural program provides neurological consultation services to the NIH Clinical Center with 24/7 coverage, 365 days a year, through the Neurology Consult Service. The service is staffed by neurological care providers who serve the patient care goals of the Clinical Center with diligence and attentiveness. The complex disease presentation of patients requiring neurological consultation is done with careful evaluation of the pathophysiological mechanism of a systemic disease or therapeutic intervention causing neurological injury.  Such investigations have led to an increased understanding of the primary disease and informed therapeutic interventions to arrest and reverse neurological injury.

The Neurology Consult Service provides inpatient and outpatient consultation services and is staffed by an in-house adult neurologist (available 24/7, with after-hours coverage provided by Clinical Fellows), pediatric neurologist, and nurse practitioners.  The inpatient team also serves as a teaching service and medical students, residents and fellows from around the country visit and do elective rotations with the service[NA([1] .

Adult outpatient neurology consultations are scheduled on Tuesday and Wednesday afternoons. Outpatient pediatric neurology services are provided on most weekdays by the in- house and visiting pediatric neurologist. The consult attending reviews patient records and collaborates with principal investigators to provide the most accurate evaluation possible. For patients with chronic care needs, the consult team participates in multidisciplinary care meetings to ensure a smooth transition to community-based care, which may include the patient’s primary care provider and outside neurology team. Consultations with neurology subspecialists may be arranged based on complexity of the disease manifestation.

Weekly Consult Conference Rounds

The NINDS Neurology Consult Service holds case conference every Thursday morning at 9 am at 7C101. Attendance is recorded, and permission to attend is required due to patient-sensitive information discussed during these conferences. This forum encourages open and candid discussions about complex disease presentations, generating rich dialogue regarding evaluation and treatment of rare and elusive neurological diseases. Providers from other institutes are welcome to attend and present cases even if the patient has not been evaluated by the NINDS consultation service.

Types of Diseases Seen on the Consult Service

Every patient seen by the Neurology Consult Service is enrolled in a research protocol at the NIH. While the service does not manage or maintain any primary protocols, it provides vital insight, assessment, and recommendations on consult requests ranging from phenotyping to therapeutics discussion on rare and complex diseases, including neuroinflammatory, neuroinfectious and oncologic conditions. The neurological manifestations of such are often unknown and/or poorly described. As such, the role of the Neurology Consult Service is invaluable in defining the extent of disease and recording complications of therapeutic interventions.

     A few examples of such diseases are:

  1. Edheim-Chester disease
  2. STAT1 mutations
  3. HIV-associated motor neuron disease
  4. Common Variable Immune Deficiency (CVID) related brain lesions
  5. CAR TIL Therapy for B-Cell lymphomas, glioblastoma multiforme (GBM), multiple myeloma
  6. McCune Albright Syndrome
  7. Autoimmune polyendrocinepathy-candidiasis-ectodermal dystrophy (APECED)
  8. Neurocysticercosis
  9. Chronic cryptococcal meningitis with spinal arachnoiditis in non-immunocompromised
  10. Cancer immunotherapy-related neurological complications including intrathecal methotrexate-related complications with stroke-like episodes, PRES, cyclosporine-induced neurological toxicity
  11. SLE-related neurological involvement
  12. Lyme disease-related neurological involvement
  13. Phelan McDermid Syndrome and epilepsy
Lumbar Puncture Service

The Neurology Consult Service assists with lumbar punctures for complicated patients who are enrolled in protocols at the NIH. The service is currently very limited but plans to expand it in the future with ultrasound-guided lumbar punctures. Contact the neurology consult service at the number listed below with questions regarding the feasibility of acquiring such services.

Outpatient Clinic Days

The Adult Neurology Clinic Days are Tuesdays and Wednesdays from 1-5 pm.  

Consultations are performed at various outpatient clinics at the Clinical Center depending on the protocol in which the patient is enrolled. Each consult requires preparation, and previous records, including neuroimaging and neurological evaluations, as well as the reason for the consultation, should be received in advance of the appointment. Disposition for chronic care needs will be addressed during the initial consultation request. Please call the number listed below for further information.

Urgent neurological consultations (same day consults) should be communicated directly to the consult attending of the day.

Emergent consultations should be obtained via activating the brain code services.

Pediatric Neurology Clinic Days are with Drs. Ariane Soltados and  Andrea Gropman.

Neurology Education Series

The Neurology Consult Service provides “Improving in Clinical Neurology” education series for practicing neurological care teams. These lectures are brief, focused on clinical care and are updates on current practices. They are held in conjunction with the weekly Consult Conference Rounds in the 7C101 conference room and are announced with some advanced notice. Previous topics include:

  • Pediatric Neurology Update (Dr. Ariane Soldatos)
  • Stroke Update (Dr. John Lynch)
  • Paroxysmal Movement Disorders (Dr. Barbara Karp)
  • Status Epilepticus Management (Dr. Shubhi Agrawal)
  • Neurosarcoidosis (Dr. Yasir Jassam)

The Neurology Consult Service serves as a starting point for clinical rotators who are completing elective rotations from institutes around the country and world. These include medical students, neurology residents and fellows at various stages of training.  After obtaining permission from the consult attending, NIH Summer students and IRTAs may observe clinical discussions to gain an understanding of how neurological care is approached, an invaluable opportunity before embarking on the journey to medical graduate sciences and medical school[NA([2] .

Patient Quality Improvement Efforts

The NINDS Neurology Consult Service has significantly advanced patient-centered quality improvement efforts at the Clinical Center. Initiatives include the establishment of the NINDS Clinical Practice Committee, participation in hospital wide M&M rounds, and the NINDS Patient Safety M&M rounds. The NINDS Patient Safety M&M rounds include areas such as:

  • Structuring Patient Follow-up on NINDS protocols
  • Stroke Management at the NIH Clinical Center
  • Approaching a "Brain Code" at NIH

Lecture series known as "Improving in Clinical Neurology" have included topics such as:

  • Pediatric Neurology Updates
  • Stroke updates
  • Paroxysmal Movement Disorders
  • Status Epilepticus Management
  • Neurosarcoidosis
  • Tremor Electrophysiology


Additional NINDS Partner & NIH Shared Facilities 


Histopathological changes in COVID-19 olfactory bulb.  Caption: Multiplex fluorescence IHC mapping of vascular (image 1) and neural cells (image 2) in the olfactory bulb of a COVID-19 patient. Credit: Dragan Maric/Avi Nath